Sublocade Treatment Guide
Sublocade is a long-acting injectable form of buprenorphine used to treat moderate-to-severe opioid use disorder in adults.
Instead of taking buprenorphine as a daily tablet or film, Sublocade releases medication gradually from an injection placed under the skin. After the initial treatment phase, injections are generally given once a month by a healthcare professional. FDA Access Data
Sublocade is one form of buprenorphine, a partial opioid agonist that can reduce opioid withdrawal and cravings and reduce the rewarding effects of other opioids. SAMHSA
For the broader medication category, see buprenorphine treatment for opioid use disorder.
Sublocade at a Glance
Sublocade is one of several FDA-approved buprenorphine products for OUD. Other options include daily transmucosal buprenorphine products and another extended-release injectable, Brixadi. NCTR CRS
How Does Sublocade Work?
Sublocade forms a medication depot under the skin that gradually releases buprenorphine.
Buprenorphine is a partial opioid agonist. It activates opioid receptors less strongly than full agonists such as heroin or methadone while helping reduce withdrawal symptoms and cravings. SAMHSA
The extended-release formulation is designed to maintain buprenorphine exposure over the month without requiring a daily tablet or film.
That can be useful for people who prefer not to manage a daily medication, have difficulty remembering daily doses, or want treatment that is administered directly by a healthcare professional.
It does not, however, mean treatment becomes “set it and forget it.” Clinical follow-up and broader OUD care still matter.
Who Can Start Sublocade?
Current FDA labeling allows Sublocade for adults with moderate-to-severe OUD who either:
• have started treatment with a single dose of transmucosal buprenorphine, or
• are already being treated with buprenorphine. FDA Access Data
This is an important update.
Older articles may say that everyone must first take Suboxone or another oral/buccal buprenorphine product for seven days or longer before receiving Sublocade. That information reflects older labeling.
Under the newer FDA label, a patient who is not currently on buprenorphine can receive an observed transmucosal buprenorphine dose to establish tolerability and, if clinically appropriate, may receive the first Sublocade injection that same day. The patient is then monitored in a healthcare setting for worsening withdrawal or sedation. FDA Access Data
This is a clinician-managed process. A person should not attempt to time buprenorphine initiation or withdrawal based on an online guide.
What Happens at the First Sublocade Appointment?
Clinical Assessment
The provider reviews opioid use, withdrawal, other substances, medications, medical history, previous OUD treatment, and treatment goals.
Confirm Buprenorphine Tolerability
Someone already receiving buprenorphine may be able to transition directly. A person not currently taking buprenorphine receives a clinician-supervised transmucosal dose first. FDA Access Data
Sublocade Is Injected
Only a healthcare professional administers Sublocade.
Observation
The FDA label calls for monitoring after the first injection for possible worsening withdrawal or sedation before leaving the healthcare setting. FDA Access Data
Follow-Up
The second injection may occur sooner than a full month in certain clinically directed situations, while subsequent maintenance injections are generally monthly. The treating provider determines the exact schedule.
Where Is Sublocade Injected?
Current FDA labeling allows Sublocade to be injected into subcutaneous tissue in four areas:
Injection sites should be rotated between doses. FDA Access Data
This is another area where older online content can be outdated. Sublocade was previously described as an abdomen-only injection, but FDA expanded the approved administration sites in 2025. U.S. Food and Drug Administration
A small lump may remain at the injection site for several weeks as the medication depot gradually decreases. The FDA label advises patients not to rub or massage the area. FDA Access Data
Can You Give Yourself Sublocade?
Healthcare Provider Only — No Self-InjectionNo.
Sublocade is available only through the Sublocade REMS Program because injecting the product into a vein could cause serious harm or death.
The medication forms a solid mass when it contacts body fluids, which can cause vascular blockage, tissue damage, or potentially life-threatening complications if injected intravenously. FDA Access Data
Sublocade is not dispensed directly to patients from a retail pharmacy.
A certified healthcare setting obtains the medication, and a healthcare professional administers the injection. FDA Access Data
This is substantially different from prescription buprenorphine films or tablets that a patient takes at home.
How Effective Is Sublocade?
In the pivotal 24-week randomized, placebo-controlled trial, treatment success was defined as having at least 80% opioid-free weeks during the evaluated treatment period.
All groups also received structured psychosocial support. FDA Access Data
These results show that Sublocade had clinically meaningful efficacy in the study population, but they should not be interpreted as guaranteeing the same outcome for every patient.
The trial also used an older buprenorphine stabilization approach before randomization, whereas current FDA labeling now permits more rapid initiation in appropriate patients. FDA Access Data
Sublocade vs. Daily Suboxone: What's the Difference?
| Sublocade | Suboxone / Daily Buprenorphine-Naloxone | |
|---|---|---|
| Buprenorphine-based | Yes | Yes |
| Form | Long-acting injection | Film/tablet |
| Dosing pattern | Generally monthly | Usually taken regularly at home |
| Provider administration | Required | Usually self-administered as prescribed |
| Retail pharmacy | Not directly dispensed to patient | Often pharmacy-dispensed |
| Missed daily doses | Not applicable in the same way | Daily adherence matters |
| Removal after administration | Not normally possible | Individual doses can be stopped under clinician guidance |
Neither format is automatically the right choice for everyone.
Some people value the convenience and medication consistency of a monthly injection. Others prefer the flexibility of transmucosal buprenorphine.
For the full comparison, see Suboxone vs. Sublocade.
Sublocade vs. Brixadi
Sublocade
Primarily a monthly treatment using extended-release buprenorphine.
Brixadi
Includes both weekly and monthly extended-release buprenorphine formulations. NCTR CRS
Both Sublocade and Brixadi are extended-release buprenorphine injections for OUD, but they are different FDA-approved products with different formulations, strengths, dosing options, and initiation instructions.
Patients should not assume that doses or schedules can be directly converted between the two products.
What Are Common Sublocade Side Effects?
In FDA clinical studies, adverse reactions reported in at least 5% of Sublocade-treated participants included:
Most injection-site reactions in clinical trials were mild to moderate, although serious injection-site complications can occur. FDA Access Data
For people using more than one substance, see MAT for people using multiple substances.
Why Should Naloxone Still Be Available?
Sublocade + Naloxone Access
Being treated with Sublocade does not eliminate every future overdose risk.
The FDA label advises healthcare professionals to discuss access to naloxone when Sublocade is initiated or renewed because people receiving OUD treatment may still experience relapse or opioid exposure. FDA Access Data
Naloxone is not a replacement for Sublocade.
Sublocade treats OUD over time, while naloxone is used in an emergency to reverse opioid overdose.
Continue to naloxone and MAT for more information.
How Long Can Someone Stay on Sublocade?
There is no universal short endpoint for buprenorphine treatment.
SAMHSA states that buprenorphine treatment duration should be individualized and may, in some cases, continue indefinitely. SAMHSA
Sublocade treatment should therefore not automatically stop after a fixed number of injections.
The clinician and patient can reassess cravings, opioid use, side effects, treatment goals, stability, and preferences over time.
Another important difference with Sublocade is that buprenorphine can remain detectable for several months after the final injection, so medication interactions, pain management, and other clinical considerations can continue after treatment stops. FDA Access Data
Read how long MAT treatment can last for the broader explanation.
Who May Prefer a Monthly Injection?
A monthly injectable may be worth discussing when someone:
• does not want to manage medication every day,
• has difficulty taking daily doses consistently,
• prefers provider-administered medication,
• is concerned about medication loss or diversion, or
• wants a long-acting buprenorphine option.
But a monthly injection also has tradeoffs.
It requires an in-person administration visit, cannot simply be stopped the next day after injection, and remains in the body for an extended period.
A clinician and patient should compare those practical differences before choosing between Sublocade and another MOUD option.
Daily Adherence
Whether managing daily medication is practical.
Privacy
Some people prefer less daily medication handling.
Medication Storage
Provider administration removes home storage needs for the injection.
Clinic Access
Monthly in-person administration still requires reliable access to a provider.
Personal Preference
Treatment choice should reflect informed preference and clinical fit.
How to Find a Sublocade Provider
Not every clinician who prescribes buprenorphine necessarily administers Sublocade.
Buprenorphine Treatment
Ask whether the provider offers buprenorphine-based OUD care.
Sublocade Administration
Do you currently administer Sublocade?
New Patients
Are you accepting new OUD patients?
Insurance
Medication coverage, prior authorization, and clinic charges can vary.
Follow-Up Care
Ask how frequently follow-up occurs beyond the injection appointment.
Can you start patients who are not already taking buprenorphine? Current labeling allows a rapid initiation pathway, but not every practice necessarily offers it.
Start with the buprenorphine treatment provider directory or the broader MAT clinic directory.
Frequently Asked Questions About Sublocade
What is Sublocade?
Sublocade is an FDA-approved extended-release buprenorphine injection for adults with moderate-to-severe opioid use disorder who have initiated transmucosal buprenorphine or are already receiving buprenorphine. FDA Access Data
Is Sublocade given every month?
After the initial treatment phase, Sublocade is generally administered monthly, with maintenance injections spaced at least 26 days apart under the FDA label. FDA Access Data
Do you have to take Suboxone for a week before Sublocade?
Not under current FDA labeling. Since the 2025 label update, an appropriate patient who is not already taking buprenorphine may start after a single supervised transmucosal buprenorphine dose confirms tolerability. FDA
Can Sublocade be given on the first day?
Potentially, yes. Current labeling permits same-day Sublocade initiation after clinician-supervised transmucosal buprenorphine in an appropriate patient who tolerates it. FDA Access Data
Can I inject Sublocade myself?
No. Sublocade must be administered by a healthcare provider through its restricted REMS distribution system. FDA Access Data
Can I pick up Sublocade from a pharmacy?
It is not dispensed to the patient through an ordinary retail-pharmacy model. Certified pharmacies and healthcare settings handle the medication under the Sublocade REMS program so it can be administered by a healthcare provider. FDA Access Data
Where can Sublocade be injected?
Current FDA labeling permits the abdomen, thigh, buttock, or back of the upper arm. FDA Access Data
Is Sublocade the same as Suboxone?
No. Both contain buprenorphine, but Sublocade is an extended-release injection containing buprenorphine, while Suboxone is a transmucosal combination of buprenorphine and naloxone.
Does Sublocade completely block fentanyl or heroin?
Sublocade can reduce opioid effects, cravings, and withdrawal, but no patient should assume it makes additional opioid use safe. Exposure to opioids or other sedating substances can still create serious risks.
How long does Sublocade stay in the body after stopping?
The FDA label states that detectable buprenorphine levels may persist for several months after the final Sublocade injection. FDA Access Data
Find Sublocade Treatment
Sublocade provides a long-acting buprenorphine option for adults with opioid use disorder who prefer or may benefit from provider-administered treatment rather than managing a daily medication.
The important questions are whether buprenorphine is appropriate, whether the provider offers Sublocade, how treatment will begin, and what ongoing support will accompany the monthly injection.
Important Safety Information
This page provides general educational information about Sublocade and buprenorphine treatment for opioid use disorder. It is not individualized medical advice.
Sublocade must be administered by an appropriately certified healthcare professional. Do not attempt to inject, remove, change, or otherwise manipulate a Sublocade depot yourself.
Buprenorphine can cause serious breathing problems, particularly when combined with alcohol, benzodiazepines, other opioids, or other central nervous system depressants. FDA Access Data